Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361375 | 0.79 | HPGD (0.60) | RAB9ANPC1ALDH1A1KMT2AGAA | |
| SCHEMBL14095958 | 0.78 | HPGD (0.51) | RAB9ANPC1ALDH1A1POLBKMT2A | |
| SCHEMBL3428205 | 0.77 | HDAC3 (0.53) | RAB9ANPC1ALDH1A1KMT2AGAA | |
| SCHEMBL11356835 | 0.76 | HDAC8 (0.64) | RAB9ANPC1ALDH1A1KMT2AGAA | |
| SCHEMBL23453329 | 0.76 | SMN1; SMN2 (0.69) | RAB9ANPC1ALDH1A1POLBKMT2A | |
| SCHEMBL23453331 | 0.76 | SMN1; SMN2 (0.65) | RAB9ANPC1ALDH1A1POLBKMT2A | |
| SCHEMBL11215485 | 0.75 | HDAC8 (0.62) | RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL4542424 | 0.75 | KMT2A (0.48) | RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL4542420 | 0.75 | KMT2A (0.48) | RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL22678459 | 0.75 | HPGD (0.81) | ALDH1A1POLBKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | RAB9A 3144/4885NPC1 886/4885ALDH1A1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.